Your browser doesn't support javascript.
loading
A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers.
Zhang, Ming; Ferrari, Raffaele; Tartaglia, Maria Carmela; Keith, Julia; Surace, Ezequiel I; Wolf, Uri; Sato, Christine; Grinberg, Mark; Liang, Yan; Xi, Zhengrui; Dupont, Kyle; McGoldrick, Philip; Weichert, Anna; McKeever, Paul M; Schneider, Raphael; McCorkindale, Michael D; Manzoni, Claudia; Rademakers, Rosa; Graff-Radford, Neill R; Dickson, Dennis W; Parisi, Joseph E; Boeve, Bradley F; Petersen, Ronald C; Miller, Bruce L; Seeley, William W; van Swieten, John C; van Rooij, Jeroen; Pijnenburg, Yolande; van der Zee, Julie; Van Broeckhoven, Christine; Le Ber, Isabelle; Van Deerlin, Vivianna; Suh, EunRan; Rohrer, Jonathan D; Mead, Simon; Graff, Caroline; Öijerstedt, Linn; Pickering-Brown, Stuart; Rollinson, Sara; Rossi, Giacomina; Tagliavini, Fabrizio; Brooks, William S; Dobson-Stone, Carol; Halliday, Glenda M; Hodges, John R; Piguet, Olivier; Binetti, Giuliano; Benussi, Luisa; Ghidoni, Roberta; Nacmias, Benedetta.
Afiliação
  • Zhang M; Shanghai First Rehabilitation Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Ferrari R; Institute for Advanced Study, Tongji University, Shanghai, China.
  • Tartaglia MC; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
  • Keith J; Department of Molecular Neuroscience, Institute of Neurology, UCL, London, UK.
  • Surace EI; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
  • Wolf U; Krembil Neuroscience Center, University Health Network Memory clinic, Toronto Western Hospital, Toronto, ON, Canada.
  • Sato C; Department of Medicine, Division of Neurology, University of Toronto, Toronto, ON, Canada.
  • Grinberg M; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
  • Liang Y; Laboratorio de Biología Molecular, Departamento de Neuropatología, Instituto de Investigaciones Neurológicas Dr. Raúl Carrea (FLENI), Buenos Aires, Argentina.
  • Xi Z; Baycrest Health Science, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Dupont K; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
  • McGoldrick P; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
  • Weichert A; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
  • McKeever PM; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
  • Schneider R; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
  • McCorkindale MD; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
  • Manzoni C; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
  • Rademakers R; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
  • Graff-Radford NR; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
  • Dickson DW; Department of Medicine, Division of Neurology, University of Toronto, Toronto, ON, Canada.
  • Parisi JE; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
  • Boeve BF; Department of Molecular Neuroscience, Institute of Neurology, UCL, London, UK.
  • Petersen RC; School of Pharmacy, University of Reading, Whiteknights, Reading, UK.
  • Miller BL; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Seeley WW; Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.
  • van Swieten JC; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • van Rooij J; Department of Laboratory Medicine and Pathology and Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Pijnenburg Y; Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • van der Zee J; Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Van Broeckhoven C; Department of Neurology, University of California San Francisco Memory and Aging Center, San Francisco, CA, USA.
  • Le Ber I; Department of Neurology and Department of Pathology, University of California San Francisco Memory and Aging Center, San Francisco, CA, USA.
  • Van Deerlin V; Department of Neurology, Erasmus MC, Rotterdam, The Netherlands.
  • Suh E; Department of Neurology, Erasmus MC, Rotterdam, The Netherlands.
  • Rohrer JD; Alzheimer Center, VU University Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands.
  • Mead S; Neurodegenerative Brain Diseases, Center of Molecular Neurology, VIB, Antwerp, Belgium.
  • Graff C; Laboratory of Neurogenetics, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
  • Öijerstedt L; Neurodegenerative Brain Diseases, Center of Molecular Neurology, VIB, Antwerp, Belgium.
  • Pickering-Brown S; Laboratory of Neurogenetics, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
  • Rollinson S; Sorbonne Universités, UPMC Univ Paris 06, Inserm U1127, CNRS UMR 7225, Institut du Cerveau et la Moelle épinière (ICM), Paris, France.
  • Rossi G; Reference Center for Rare and Young Dementias, Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, Hopital Pitié-Salpêtrière, Paris, France.
  • Tagliavini F; Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
  • Brooks WS; Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
  • Dobson-Stone C; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
  • Halliday GM; MRC Prion Unit at UCL, Institute of Prion Diseases, London, UK.
  • Hodges JR; Division of Neurogeriatrics, Alzheimer Research Center, Karolinska Institutet, Solna, Sweden.
  • Piguet O; Genetics Unit, Theme Aging, Karolinska University Hospital, Stockholm, Sweden.
  • Binetti G; Division of Neurogeriatrics, Alzheimer Research Center, Karolinska Institutet, Solna, Sweden.
  • Benussi L; Genetics Unit, Theme Aging, Karolinska University Hospital, Stockholm, Sweden.
  • Ghidoni R; Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, University of Manchester, UK.
  • Nacmias B; Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, University of Manchester, UK.
Brain ; 141(10): 2895-2907, 2018 10 01.
Article em En | MEDLINE | ID: mdl-30252044
The G4C2-repeat expansion in C9orf72 is the most common known cause of amyotrophic lateral sclerosis and frontotemporal dementia. The high phenotypic heterogeneity of C9orf72 patients includes a wide range in age of onset, modifiers of which are largely unknown. Age of onset could be influenced by environmental and genetic factors both of which may trigger DNA methylation changes at CpG sites. We tested the hypothesis that age of onset in C9orf72 patients is associated with some common single nucleotide polymorphisms causing a gain or loss of CpG sites and thus resulting in DNA methylation alterations. Combined analyses of epigenetic and genetic data have the advantage of detecting functional variants with reduced likelihood of false negative results due to excessive correction for multiple testing in genome-wide association studies. First, we estimated the association between age of onset in C9orf72 patients (n = 46) and the DNA methylation levels at all 7603 CpG sites available on the 450 k BeadChip that are mapped to common single nucleotide polymorphisms. This was followed by a genetic association study of the discovery (n = 144) and replication (n = 187) C9orf72 cohorts. We found that age of onset was reproducibly associated with polymorphisms within a 124.7 kb linkage disequilibrium block tagged by top-significant variation, rs9357140, and containing two overlapping genes (LOC101929163 and C6orf10). A meta-analysis of all 331 C9orf72 carriers revealed that every A-allele of rs9357140 reduced hazard by 30% (P = 0.0002); and the median age of onset in AA-carriers was 6 years later than GG-carriers. In addition, we investigated a cohort of C9orf72 negative patients (n = 2634) affected by frontotemporal dementia and/or amyotrophic lateral sclerosis; and also found that the AA-genotype of rs9357140 was associated with a later age of onset (adjusted P = 0.007 for recessive model). Phenotype analyses detected significant association only in the largest subgroup of patients with frontotemporal dementia (n = 2142, adjusted P = 0.01 for recessive model). Gene expression studies of frontal cortex tissues from 25 autopsy cases affected by amyotrophic lateral sclerosis revealed that the G-allele of rs9357140 is associated with increased brain expression of LOC101929163 (a non-coding RNA) and HLA-DRB1 (involved in initiating immune responses), while the A-allele is associated with their reduced expression. Our findings suggest that carriers of the rs9357140 GG-genotype (linked to an earlier age of onset) might be more prone to be in a pro-inflammatory state (e.g. by microglia) than AA-carriers. Further, investigating the functional links within the C6orf10/LOC101929163/HLA-DRB1 pathway will be critical to better define age-dependent pathogenesis of frontotemporal dementia and amyotrophic lateral sclerosis.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Regulação da Expressão Gênica / Demência Frontotemporal / Proteína C9orf72 / Esclerose Lateral Amiotrófica Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Regulação da Expressão Gênica / Demência Frontotemporal / Proteína C9orf72 / Esclerose Lateral Amiotrófica Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article